Financial evaluation of vaccination and testing alternatives for control of parvovirus-induced reproductive failure in swine

Objective

To identify the preferable testing and vaccination strategy for control of porcine parvovirus (PPV) during a 6-month period.

Design

Decision-tree analysis and computer simulations.

Sample Population

Computer modeling of 300-sow farrow-to-finish herd.

Procedure

Serologic testing of 30 females to estimate herd PPV prevalence versus not testing any females was the initial decision alternative. On the basis of serologic test results, herds were classified into 1 of 3 PPV-risk categories: low (≥ 80% seropositive females), moderate (40 to < 80% seropositive females), or high (< 40% seropositive females). Vaccinating all females, only gilts, or not vaccinating was the second decision alternative.

Results

For initial model assumptions (test sensitivity and specificity = 0.95; test cost = $5/female; vaccination cost = $0.30/dose; vaccination efficacy = 0.95; and foregone gross margin = $10.85/pig), vaccination of all females (with or without serologic testing) was preferable, but the financially preferable option was to omit serologic testing. Most profitable vaccination option varied with foregone gross margin, vaccination cost, and efficacy. For herds in which all sows were known to be immune, vaccinating only gilts was financially preferable, and serologic testing was not warranted. Variation in expected monetary losses was less in vaccination options than with nonvaccination.

Clinical Implications

For most herds in the United States, serologic screening for PPV prior to selection of a vaccination program is unlikely to be cost-effective, because vaccination is inexpensive ($0.30/dose) and effective (95%). At current profit margins ($10.85/pig), vaccination of all females has the least-risk and is the preferred option.

Authors: Ian A. Gardner, Tim E. Carpenter, Leonidas Leontides, Thomas D. Parsons

Source: https://avmajournals.avma.org/

Like0

Dislike0

List
Add

Please enter a comment

Name *

Email address *

Comment *

* Required fields

Information on the processing of your personal data
We inform you that, in compliance with the provisions of current national and European regulations for the Protection of Personal Data and Services of the Information Society and Electronic Commerce, by sending us this form you are expressly giving your consent to Grupo Asís Biomedia , SL, (hereinafter, "ASIS GROUP") so that, as the person in charge, it may process your personal data in order to respond to your request for contact and information by electronic means.

Likewise, when you expressly consent, we will process your personal data to send you specialized information, newsletters, offers and exclusive promotions from GRUPO ASIS and related companies.

For the aforementioned purpose, GRUPO ASIS may transfer your data to other companies linked to GRUPO ASIS or to third party service providers for the management of electronic communications and other security services, even in cases where they are outside of the European Union, provided that they legally guarantee the adequate level of protection required by European regulations.

At any time you can withdraw the consent given and exercise the rights of access, rectification, deletion, portability of your data and limitation or opposition to its treatment by contacting GRUPO ASIS by sending an email to protecciondatos @ grupoasis.com, or by written communication to address at Centro Empresarial El Trovador, 8th floor, office I, Plaza Antonio Beltrán Martínez 1, 50002, Zaragoza (Spain), indicating in either case the Ref. Personal data and the right you exercise, as well as attaching a copy of your ID or replacement identification document.

I have read and accept the treatment of my data according to the informed purpose and according Legal notes and the Privacy Policy
I wish to receive commercial information from GRUPO ASIS and related companies